LOCOREGIONAL CHEMOTHERAPY VERSUS LOCOREGIONAL COMBINED IMMUNOCHEMOTHERAPY FOR PATIENTS WITH ADVANCED METASTATIC LIVER-DISEASE OF COLORECTALORIGIN - A PROSPECTIVE RANDOMIZED STUDY

Background/Aims: This reports presents the results of a prospective ra ndomized controlled study, of combined locoregional targeted immuno-ch emotherapy for treatment of patients with liver metastasis from primar y colorectal malignancies. Materials and Methods: Forty eight patients were randomly assigned into one of two groups. Group A (n=15) include d patients who had post-operatively locoregional chemotherapy and Grou p B (n=33) included patients who had combined locoregional immuno-chem otherapy. Results: Statistical analysis shows a clear superiority in. the survival and responses of patients treated with immuno-chemotherap y versus chemotherapy alone. Forty five percent of patients in. Group B are alive with a mean survival of 20.3 months, ranging from 13 to 29 months, as opposed to no survivors from Group A and a mean, survival of only 9.9 months, ranging from 3.6 to 22.5 months. Additionally, 64% of the immuno-chemotherapy group had a positive response while only 1 3% of the chemotherapy had such a response. Conclusions: Our data supp orts the value of combined immuno-chemotherapy as a treatment for adva nced metastatic liver disease.